Optimierung der Galenik von Analgetika zur Behandlung chronischer Schmerzzustände

Schlüsselwörter

Schmerzpflaster - End-of-dose-Versagen - Retardpräparat - Dose-Dumping

Keywords

transdermal patches - end-of-dose-failure - extended-release products - dose dumping

Literatur

• 1 Ackerman S J, Mordin M, Reblando J. et al . Patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release among patients with chronic nonmalignant pain.  J Manag Care Pharm. 2003;  9 223-231
• 2 Drover D R, Angst M S, Valle M. et al . Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers.  Anesthesiology. 2002;  97 827-836
• 3 Gallagher R M, Welz-Bosna M, Gammaitoni A. Assessment of dosing frequency of sustained-release opioid preparations in patients with chronic nonmalignant pain.  Pain Med. 2007;  8 71-74
• 4 Grond S, Radbruch L, Lehmann K A. Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl.  Clin Pharmacokinet. 2000;  38 59-89
• 5 Miaskowski C. Pharmacologic management of sleep disturbances in noncancer-related pain.  Pain Management Nursing. 2008; 
• 6 Palangio M, Northfelt D W, Portenoy R K. et al . Dose conversion and titration with a novel, once-daily, OROS® osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain.  J Pain Symptom Manage. 2002;  23 355-368
• 7 Radbruch L, Sabatowski R, Petzke F. et al . Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients.  Palliat Med. 2001;  15 309-321
• 8 Sathyan G, Guo C, Sivakumar K. et al . Evaluation of the bioequivalence of two transdermal fentanyl systems following single and repeat applications.  Current Medical Research and Opinion. 2005;  21 1961-1968
• 9 Turk D C, Dworkin R H, Revicki D. et al . Identifying important outcome domains for chronic pain clinical trials: An IMMPACT survey of people with pain.  Pain. 2008;  137 276-285
• 10 Visionenfür eine optimierte Opioidtherapie – 12. SocraTec Expertengespräch.  Deutsche Apotheker Zeitung (DAZ). 2007;  147 49-50
• 11 World Health Organisation .Cancer pain release appraising the Who Analgesic Ladder on its 20th anniversary. Geneve; WHO 2006
• 12 Wonnemann M, Schug B, Schmücker K. et al . Significant food interactions observed with a nifedipine modified-release formulation marketed in the European Union.  Intern J Clin Pharmacol Therapeut. 2006;  44 38-48
• 13 Wonnemann M, Schug B, Anschütz M. et al . Comparison of two marketed nifedipine modified-release formulation: An exploratory clinical food interaction study.  Clin Therapeutics. 2008;  30 1-11